Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
GlaxoSmithKline (United States) · South College
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
605
total citations
- FWCI
- 33.02
- Percentile
- 100%
- References
- 131
Citations per year
Authors
1Topics & keywords
Topics
Keywords
- Ipilimumab
- Nivolumab
- Medicine
- Immunotherapy
- Oncolytic virus
- Drug development
- Cancer immunotherapy
- Oncology
No related works found for this paper.